Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
Bibliographic Data
| ID | 22077183 |
|---|---|
| Authors | Zhuo-miao Ye, Zhuo‐miao Ye (Central South University), Zhe Xu (0000-0002-0186-2978, Central South University), Huan Li (0000-0003-0910-1433, Central South University), Qian Li (0000-0003-1286-8539, Changsha Central Hospital, corresponding author) |
| Year | 2023 |
| Volume | 11 |
| Pages | 1046424-1046424 |
| Publication date | 2023-02-10 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1046424 |
| PMID | 36844853 |
| OpenAlex | W4319984288 |
| Language | EN |
| Citations received | 1 |
| References cited | 47 |
Objective: The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effectiveness of durvalumab plus chemotherapy compared to placebo plus chemotherapy from the perspective of US and Chinese payers. Methods: Based on clinical data from the TOPAZ-1 trial, a Markov model was developed to simulate 10-year life expectancy and total healthcare costs for patients with BTC. The treatment group received durvalumab in combination with chemotherapy and the control group received placebo plus chemotherapy. The primary outcomes analyzed included quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). Uncertainty in the analysis results was assessed by sensitivity analysis. Results: For US payers, the placebo plus chemotherapy group had a total cost of $56,157.05 and a utility of 1.10 QALYs, while the durvalumab plus chemotherapy group had a total cost of $217,069.25, a utility of 1.52 QALYs, resulting in an ICER of $381,864.39/QALY. For Chinese payers, the ICER of durvalumab plus chemotherapy group was $367,608.51/QALY. Sensitivity analysis showed that the analysis was most sensitive to the price of durvalumab. For US and Chinese payers, under the respective willing to pay thresholds, the likelihood of the durvalumab plus chemotherapy arm being cost-effective was 0%. Conclusions: Both in China and in the US, durvalumab in combination with chemotherapy is not a cost-effective option for the first-line treatment of BTC compared with chemotherapy
Biliary tract · Biliary tract cancer · Cancer · Chemotherapy · Durvalumab · Gemcitabine · Immunotherapy · Intensive care medicine · Cholangiocarcinoma and Gallbladder Cancer Studies · Gallbladder and Bile Duct Disorders · Medicine · Pancreatic and Hepatic Oncology Research · Internal Medicine · Oncology
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration
Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China
| Unique citing works | 1 |
|---|---|
| Citations per year | 1 |
| Citation span | 2025 - 2025 (1) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 1 |